Peter Strumph has more than two decades of experience in executive leadership and technical roles supporting successful development and commercialization for 7 FDA approved novel therapies. Peter’s prior experience includes CEO at Amygdala Neurosciences, CEO at Codexis, CEO of Nile Therapeutics, SVP of Operations at Portola Pharmaceuticals, SVP of Operations at CV Therapeutics, Manager of Operations & Planning at Biogen, and an engineer at Bayer. Peter served as a Lieutenant in the US Navy. Peter earned a BAS in Systems Engineering from the University of Pennsylvania and an MBA from the Wharton School.